卡培他滨联合表柔比星和奥沙利铂治疗晚期胃癌的临床观察

目的观察卡培他滨联合表柔比星和奥沙利铂治疗晚期胃癌的疗效及安全性。方法对19例晚期胃癌患者采用表柔比星75mg/m2静脉推注(d1),奥沙利铂130mg/m2静脉滴注2小时(d1),卡培他滨1250mg/m2口服,每天2次(d1-d14),每3周重复。2周期评价疗效及不良反应。结果全组19例患者均可评价疗效,其中完全有效2例(10.5%),部分有效8例(42.1%),稳定8例(42.1%),进展1例(5.3%),总有效率52.6%。主要不良反应为骨髓抑制及外周神经毒性,无化疗相关性死亡。结论卡培他滨联合表柔比星和奥沙利铂方案治疗晚期胃癌疗效较高,不良反应轻。

Clinical Observation of Capecitabine Combined with Epirubicin and Oxaliplatin for Patients with Advanced Gastric Cancer

Objective To observe the recent efficacy and toxicity of capecitabine combined with epirubicin and oxaliplatin for patients with advanced gastric cancer.Methods The 19 patients with advanced gastric cancer received the treatment of epirubicin 75mg/m2(d1),oxaliplatin 130mg/m2(d1) and capecitabine 1250mg/m2(dl-d14) and repeated every 3 weeks.Efficacy and toxicity were analyzed every 2 cycles.Results 19 patients were all suitable for the analysis.2 patients achieved CR(10.5%),8 PR(42.1%),8 SD(42.1%),1 PD(6.3%).The overall response rate is 52.6%.The major toxic reaction were myelosuppression and neuro-sensory toxicity.No related death occurred in this trail.Conclusion Capecitabine combined with epirubicin and oxaliplatin was well tolerated and very effective for the treatment of patients with advanced gastric cancer.